Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 5,323 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Problem Behavior, Self-injury, Communication
Interventions: Functional communication training; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 3 Years to 19 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: T Cell Leukemia, Adult, Leukemia, Adult T-Cell, T Cell Leukemia, HTLV I Associated
Interventions: Ruxolitinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Low Back Pain, Osteoarthritis, Neuropathic Pain
Interventions: EN3409; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more

Conditions: Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions: TransCon PTH, Placebo for TransCon PTH; Combination Product
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 5
States / cities: Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more

Conditions: High Risk Smoldering Multiple Myeloma
Interventions: Ibrutinib; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine, Sargramostim; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Buffalo, New York • New York, New York

Conditions: Breast Cancer, Cancer of Breast, Breast Carcinoma
Interventions: Palbociclib, Letrozole, Trastuzumab, Goserelin, Breast surgery, Research tumor biopsy, Research bone marrow (OPTIONAL), Research blood sample, Research blood for germline DNA, Blood for detection of circulating tumor cells; Drug · Biological · Procedure + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Phoenix, Arizona • St Louis, Missouri • Buffalo, New York

Conditions: Sickle Cell Disease
Interventions: sodium nitrite injection, usp; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 8 Years to 23 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Haemostasis, Healthy
Interventions: eptacog alfa (activated), clopidogrel, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Interventions: Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 50
States / cities: Fresno, California • Irvine, California • Los Alamitos, California + 43 more

Conditions: Alzheimer s Disease
Interventions: Terazosin (Hytrin), Placebo; Drug · Other
Lead sponsor: Qiang Zhang; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity
Interventions: Egg oral immunotherapy, Control Group; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 18 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Myelodysplastic Syndromes
Interventions: filgrastim, clofarabine, cytarabine, microarray analysis, biopsy; Biological · Drug · Genetic + 1 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Peanut Allergy
Interventions: Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more

Conditions: Stage III Colon Cancer
Interventions: Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month; Device · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1045
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 730 more

Conditions: Proliferative Diabetic Retinopathy (PDR)
Interventions: Aflibercept 8mg; Drug
Lead sponsor: Edward Wood, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Austin, Texas • Bellaire, Texas • San Antonio, Texas

Conditions: Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
Interventions: Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug, Change platelet transfusion threshold, Full dose antithrombotics, Mechanical measures, Intermediate dose antithrombotic; Drug · Biological · Device
Lead sponsor: Maastricht University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Schizophrenia
Interventions: Paliperidone; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Ulcerative Colitis
Interventions: IMU-838, Placebo; Drug
Lead sponsor: Immunic AG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 15
States / cities: Tucson, Arizona • Los Angeles, California • Ventura, California + 12 more

Conditions: Healthy Subjects
Interventions: GAP-134, placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Merck L-830982, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Prostate Cancer
Interventions: sipuleucel-T, enzalutamide; Biological · Drug
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 19
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 16 more

Conditions: HIV-1-infection
Interventions: ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 52
States / cities: Cullman, Alabama • Homewood, Alabama • Irvine, California + 45 more

Search by objective public record fields.

Resurgence as Choice: Basic and Clinical Studies

Ruxolitinib for Adult T-Cell Leukemia

Long-term Open-Label Safety Study to Evaluate EN3409

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Terazosin And Metabolic Engagement in Alzheimer's Disease

Oral Immunotherapy for Childhood Egg Allergy

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia

Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration